UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Ten-year results of the PORTEC-2 trial for high-intermediate risk endometrial carcinoma: improving patient selection for adjuvant therapy

British journal of cancer, 2018-10, Vol.119 (9), p.1067-1074

2018

Volltextzugriff (PDF)

A real or apparent decrease in glomerular filtration rate in patients using olaparib?

European journal of clinical pharmacology, 2021-02, Vol.77 (2), p.179-188

2021

Volltextzugriff (PDF)

Study protocols of three parallel phase 1 trials combining radical radiotherapy with the PARP inhibitor olaparib

BMC cancer, 2019-09, Vol.19 (1), p.901-13, Article 901

2019

Volltextzugriff (PDF)

Induction of thymidylate synthase as a 5-fluorouracil resistance mechanism

BBA - Molecular Basis of Disease, 2002-07, Vol.1587 (2), p.194-205

2002

Volltextzugriff (PDF)

Downstream molecular determinants of response to 5-fluorouracil and antifolate thymidylate synthase inhibitors

Annals of oncology, 2000-04, Vol.11 (4), p.385-391

2000

Volltextzugriff (PDF)

Evaluation of clinical and endoscopic toxicity after external beam radiotherapy and endorectal brachytherapy in elderly patients with rectal cancer treated in the HERBERT study

Radiotherapy and oncology, 2018-03, Vol.126 (3), p.417-423

2018

Volltextzugriff (PDF)

Safety, clinical activity and pharmacological biomarker evaluation of the DNA-dependent protein kinase (DNA-PK) inhibitor M3814: Results from two phase I trials

Annals of oncology, 2018-10, Vol.29, p.viii654-viii654

2018

Volltextzugriff (PDF)

351 Sensitive pharmacodynamic assessment of PARP inhibitors for individualized treatment in clinic

European journal of cancer (1990), 2015-09, Vol.51, p.S71-S71

2015

Volltextzugriff (PDF)

PO-0935: Correcting diffusion weighted MR images for signal pile-up and distortions near gas pockets

Radiotherapy and oncology, 2016-04, Vol.119, p.S453-S453

2016

Volltextzugriff (PDF)

OC-0621: A population based library of plans for rectal cancer: design and prospects for margin reduction

Radiotherapy and oncology, 2016-04, Vol.119, p.S295-S296

2016

Volltextzugriff (PDF)

SP-0208: Validation of imaging with histology: implications for dose prescriptions

Radiotherapy and oncology, 2016-04, Vol.119, p.S94-S94

2016

Volltextzugriff (PDF)

Results of phase I trials combining PARP inhibition and radiotherapy in multiple sites

Radiotherapy and oncology, 2016-04, Vol.119, p.S138-S138

2016

Volltextzugriff (PDF)

OC-0470: Library of plans in radiotherapy of rectal cancer: feasible and inter-observer consistent?

Radiotherapy and oncology, 2016-04, Vol.119, p.S223-S223

2016

Volltextzugriff (PDF)

PD-0182: Prediction of needle placement in the first fraction of cervix brachytherapy: pre-MRI plan versus expert opinion

Radiotherapy and oncology, 2015-04, Vol.115, p.S90-S91

2015

Volltextzugriff (PDF)

Thymidylate Synthase: A Target for Combination Therapy and Determinant of Chemotherapeutic Response in Colorectal Cancer

Oncology, 1999-10, Vol.57 (3), p.179-194

1999

Volltextzugriff (PDF)

PO-0713: Pathology of CTV of prostate cancer: implications for the dose to the tumor and the gland

Radiotherapy and oncology, 2015-04, Vol.115, p.S351-S351

2015

Volltextzugriff (PDF)

OC-0148: Evaluation of EBRT and HDRBT for inoperable rectal cancer patients: an update of the HERBERT study

Radiotherapy and oncology, 2016-04, Vol.119, p.S67-S68

2016

Volltextzugriff (PDF)

PD-0427: A pharmacodynamic assay to assess the radiosensitizing potential of PARP inhibitors in clinical trials

Radiotherapy and oncology, 2014, Vol.111, p.S170-S170

2014

Volltextzugriff (PDF)

PO-0726: Pathology of CTV of prostate cancer: Implications for the dose to the tumor and the gland

Radiotherapy and oncology, 2014, Vol.111, p.S31-S31

2014

Volltextzugriff (PDF)

OC-0617: The PARP inhibitor olaparib is effective as radiosensitizer at 10-fold lower doses than as single agent

Radiotherapy and oncology, 2015-04, Vol.115, p.S298-S299

2015

Volltextzugriff (PDF)

PD-0129: GTV and CTV in prostate cancer: distance and size of satellites relative to the index lesion

Radiotherapy and oncology, 2013-03, Vol.106, p.S48-S48

2013

Volltextzugriff (PDF)

PO-0781 POTENTIAL BENEFIT OF ADAPTIVE RADIOTHERAPY DURING CHEMO-RADIOTHERAPY OF RECTAL CANCER

Radiotherapy and oncology, 2012-05, Vol.103, p.S302-S302

2012

Volltextzugriff (PDF)

OC-0068 THE NAD+ DEPLETING AGENT APO866 ENHANCES CELL DEATH WHEN COMBINED WITH RADIATION

Radiotherapy and oncology, 2012-05, Vol.103, p.S27-S28

2012

Volltextzugriff (PDF)

OC-0497: Feasibility study of external beam radiotherapy followed by brachytherapy in inoperable rectal cancer patients

Radiotherapy and oncology, 2014, Vol.111, p.S194-S195

2014

Volltextzugriff (PDF)

OC-0159: Hydrogel spacer use for prostate cancer radiotherapy - 12 month toxicity and proctoscopy results

Radiotherapy and oncology, 2014, Vol.111, p.S61-S61

2014

Volltextzugriff (PDF)

1 – 25 von 96

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(94)
Mit Volltextzugriff
(88)

Publikationsform

Artikel
(95)
Tagungsberichte
(1)

Sprache

Erscheinungsjahr

n.n

Thema

Life Sciences & Biomedicine
(40)
Science & Technology
(40)
Humans
(28)
Hematology, Oncology And Palliative Medicine
(22)
Oncology
(13)
Female
(11)
Animals
(9)
Biochemistry & Molecular Biology
(9)
Aged
(8)
Thymidylate Synthase - Antagonists & Inhibitors
(8)
Middle Aged
(7)
Radiation Therapy
(7)
Cell Biology
(6)
Chemotherapy
(6)
Thymidylate Synthase
(6)
5-Fluorouracil
(5)
Biological And Medical Sciences
(5)
Fluorouracil - Pharmacology
(5)
Folic Acid Antagonists - Pharmacology
(5)
Medical Sciences
(5)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Ten-year results of the PORTEC-2 trial for high-intermediate risk endometrial carcinoma: improving patient selection for adjuvant therapy

A real or apparent decrease in glomerular filtration rate in patients using olaparib?

Study protocols of three parallel phase 1 trials combining radical radiotherapy with the PARP inhibitor olaparib

Induction of thymidylate synthase as a 5-fluorouracil resistance mechanism

Downstream molecular determinants of response to 5-fluorouracil and antifolate thymidylate synthase inhibitors

Evaluation of clinical and endoscopic toxicity after external beam radiotherapy and endorectal brachytherapy in elderly patients with rectal cancer treated in the HERBERT study

Safety, clinical activity and pharmacological biomarker evaluation of the DNA-dependent protein kinase (DNA-PK) inhibitor M3814: Results from two phase I trials

351 Sensitive pharmacodynamic assessment of PARP inhibitors for individualized treatment in clinic

PO-0935: Correcting diffusion weighted MR images for signal pile-up and distortions near gas pockets

OC-0621: A population based library of plans for rectal cancer: design and prospects for margin reduction

SP-0208: Validation of imaging with histology: implications for dose prescriptions

Results of phase I trials combining PARP inhibition and radiotherapy in multiple sites

OC-0470: Library of plans in radiotherapy of rectal cancer: feasible and inter-observer consistent?

PD-0182: Prediction of needle placement in the first fraction of cervix brachytherapy: pre-MRI plan versus expert opinion

Thymidylate Synthase: A Target for Combination Therapy and Determinant of Chemotherapeutic Response in Colorectal Cancer

PO-0713: Pathology of CTV of prostate cancer: implications for the dose to the tumor and the gland

OC-0148: Evaluation of EBRT and HDRBT for inoperable rectal cancer patients: an update of the HERBERT study

PD-0427: A pharmacodynamic assay to assess the radiosensitizing potential of PARP inhibitors in clinical trials

PO-0726: Pathology of CTV of prostate cancer: Implications for the dose to the tumor and the gland

OC-0617: The PARP inhibitor olaparib is effective as radiosensitizer at 10-fold lower doses than as single agent

PD-0129: GTV and CTV in prostate cancer: distance and size of satellites relative to the index lesion

PO-0781 POTENTIAL BENEFIT OF ADAPTIVE RADIOTHERAPY DURING CHEMO-RADIOTHERAPY OF RECTAL CANCER

OC-0068 THE NAD+ DEPLETING AGENT APO866 ENHANCES CELL DEATH WHEN COMBINED WITH RADIATION

OC-0497: Feasibility study of external beam radiotherapy followed by brachytherapy in inoperable rectal cancer patients

OC-0159: Hydrogel spacer use for prostate cancer radiotherapy - 12 month toxicity and proctoscopy results

Suchergebnisse filtern